Synlogic, Inc. (SYBX)

OTCMKTS · Delayed Price · Currency is USD

0.620

0.00 (0.00%)

At close: Feb 27, 2026

-55.07% (1Y)

Market Cap	7.25M
Revenue (ttm)	n/a
Net Income (ttm)	-3.23M
Shares Out	11.70M
EPS (ttm)	-0.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	229
Average Volume	8,943
Open	0.620
Previous Close	0.620
Day's Range	0.620 - 0.620
52-Week Range	0.540 - 1.960
Beta	0.53
RSI	33.80
Earnings Date	Mar 16, 2026

About Synlogic

Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The com... [Read more]

Industry Biotechnology

Sector Healthcare

CEO Mary Dooley

Employees 1

Stock Exchange OTCMKTS

Ticker Symbol SYBX

Full Company Profile

Financial Performance

In 2024, Synlogic's revenue was $8,000, a decrease of -99.76% compared to the previous year's $3.37 million. Losses were -$23.36 million, -61.88% less than in 2023.

Financial Statements

News

There is no news available yet.